Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunovia ABIMMVF -61.59%43 Debt-to-Equity is 0.01 as of Mar. 2026, which is 88% below its 10-year median of 0.08. GuruFocus rates IMMVF with a GF Score™ of 43/100 and a GF Value™ of $0.01. The stock has 4 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Immunovia AB ranks better than 99.45% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Immunovia AB's Debt-to-Equity or its related term are showing as below:
IMMVF'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.47 Med: 0.08 Max: 0.44
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Immunovia AB was 0.44. The lowest was -2.47. And the median was 0.08.
IMMVF's Debt-to-Equity is ranked better than 99.45% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.31
vs IMMVF: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Immunovia AB Debt-to-Equity Related Terms
Immunovia AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Immunovia AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMMVF vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Immunovia AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Immunovia AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB (IMMVF) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Immunovia AB and its competitors. This is 88% below median its historical median of 0.08. According to the industry distribution chart, Immunovia AB ranks #1 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 0.5%.
Is Immunovia AB's Debt-to-Equity too high?
Immunovia AB's current Debt-to-Equity of 0.01 is 88% below median its 10-year median of 0.08. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.31. Immunovia AB's value of 0.01 is 96.8% below this industry median. Based on the distribution chart, Immunovia AB ranks #1 out of 183 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Immunovia AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #1 out of 183 companies for Debt-to-Equity. This places Immunovia AB in the top 1% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.31. Immunovia AB's value of 0.01 is 96.8% below this benchmark. While the company's 10-year median is 0.08 vs. the industry median of 0.31, Immunovia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.31, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunovia AB's current Debt-to-Equity of 0.01 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Immunovia AB and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovia AB's current Debt-to-Equity is 0.01, which is 88% below median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Debt-to-Equity of 0.01. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Debt-to-Equity is 0.01, which is 88% below median its 10-year median of 0.08 and 96.8% below the Medical Diagnostics & Research industry median of 0.31. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.
Key valuation signals for IMMVF:
Debt-to-Equity: 0.01 (88% below median its 10-year median of 0.08)
GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
Industry Position: 96.8% below the Medical Diagnostics & Research median (#1 of 183)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score
Get the complete analysis for IMMVF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
